ORF_ID	Contig	Start	Stop	Orientation	Cut_Off	Pass_Bitscore	Best_Hit_Bitscore	Best_Hit_ARO	Best_Identities	ARO	Model_type	SNPs_in_Best_Hit_ARO	Other_SNPs	Drug Class	Resistance Mechanism	AMR Gene Family	Predicted_DNA	Predicted_Protein	CARD_Protein_Sequence	Percentage Length of Reference Sequence	ID	Model_ID	Nudged	Note	Hit_Start	Hit_End	Antibiotic
BGC0000919.1|Phaseolotoxin_1 # 3 # 365 # 1 # ID=1_1;partial=10;start_type=Edge;rbs_motif=None;rbs_spacer=None;gc_cont=0.499	BGC0000919.1|Phaseolotoxin_1 	3	365	+	Loose	675	25.0238	emrA	33.33	3000027	protein homolog model	n/a	n/a	fluoroquinolone antibiotic	antibiotic efflux	major facilitator superfamily (MFS) antibiotic efflux pump	AGGAACTTCGAATTCGAGGCCGATAGCCGATCCAGACCAAACCTATTCAAGCATAGCCATGACCTGTATGTGAGCGGCTCAAGAGTTGGTGTCGAATCAGCAATATCGGGTGGGATTTACGAGTTGGACTTCTGCTTCTTTCAGTCCGCGGGTGCGCAGCAGAGTAATAGTCGTGAAGAGTGCACCGCCAGAAGTGTCGTTATTCGATATGTCGGGGGGCGTAAACCCTTTGATATGGACTGTGTCCAGTCGGATATGAGTGCCCTTTCAAGTTGCCTGGTTAATACGCTGGATCTCGATTCTTCCACTCGTGAACTTTCGGAGCTCCCTAGCTGGACGTGGAATCATTTTGATATCGCATAG	RNFEFEADSRSRPNLFKHSHDLYVSGSRVGVESAISGGIYELDFCFFQSAGAQQSNSREECTARSVVIRYVGGRKPFDMDCVQSDMSALSSCLVNTLDLDSSTRELSELPSWTWNHFDIA	MSANAETQTPQQPVKKSGKRKRLLLLLTLLFIIIAVAIGIYWFLVLRHFEETDDAYVAGNQIQIMSQVSGSVTKVWADNTDFVKEGDVLVTLDPTDARQAFEKAKTALASSVRQTHQLMINSKQLQANIEVQKIALAKAQSDYNRRVPLGNANLIGREELQHARDAVTSAQAQLDVAIQQYNANQAMILGTKLEDQPAVQQAATEVRNAWLALERTRIISPMTGYVSRRAVQPGAQISPTTPLMAVVPATNMWVDANFKETQIANMRIGQPVTITTDIYGDDVKYTGKVVGLDMGTGSAFSLLPAQNATGNWIKVVQRLPVRIELDQKQLEQYPLRIGLSTLVSVNTTNRDGQVLANKVRSTPVAVSTAREISLAPVNKLIDDIVKANAG	30.77	gnl|BL_ORD_ID|1610|hsp_num:0	1757			144	216	nalidixic acid
BGC0000919.1|Phaseolotoxin_2 # 567 # 1508 # 1 # ID=1_2;partial=00;start_type=ATG;rbs_motif=AGGA;rbs_spacer=5-10bp;gc_cont=0.541	BGC0000919.1|Phaseolotoxin_2 	567	1508	+	Loose	600	26.1794	vanS gene in vanP cluster	27.78	3007192	protein homolog model	n/a	n/a	glycopeptide antibiotic	antibiotic target alteration	vanS; glycopeptide resistance gene cluster	ATGGAATTGTCTTCCGCTGTGCAAGATTTCGTTAAAAAGAATGCACAAGACTTTCTCGGGGCTCGAAATATAGGCTTCAACTTCCTCAATGAAGTTGCTTCCCGTCAGTGCGATCCTGGAACACTTCTACTCACCAGTTCGGCGGTCCATGGTATTGCCACCATGGCCAGCGATATTGATATGTTGTGCGTGGTTGACGAGCCTGTCAGCACCGAGCAAATGGCAACCCAGATTCATCAGGAAGGTCTGCATCTCGAACTGTTGCTGTTCAATGCTGCCGATGTTCACTTGGCCCTTGGCGAACTCACCAGCCTGGCGCAAAGCCCAGCGCTGATCTGCCTGCAAAATTATTCAAGATGGGATAAGCGCAACAAGGTTCCGCGCAAATATGTCGAGCGCTTGGTCTATGGCGTGACCAATGATCTCACCACTCCTTATCTCTCGGCACTTGGCGACCTGTGTGTCGTGGTGTCTCGCAAAGACCTGGATGTTTTCAGAGTGAATGTCGCCTGCTCACGGCTGGCGCAACGGTCTGACGAGCCTTTTGCGGCGATCGGCTATTTGATGAATGCACTGACCGCAGCCATGAACTCGCTGCTTTCGATGTCGGGTTGGGTGTTGTCCAACAAGAAGTGGACGCTGCGTCGCTGGAATAAAAGCCGCGACCTGGTTTTCTTGGATCTTTGCCCTACCACCTGGACGGAGGTTTCAGCGCTCTGGGCAGACCTTGCGAAAGGTCCAGCGGTGTTGGACGAAGCCCTGTCACGCATCGAGACGTTATTGCAGCAAATGACAGGCAGGCTGGCTCCGGAACTCCTTCGTGATGAACCATTTACCGGGTTGCAGGGAAATGTTGCGCGGTATCCGTTGCACGCCAAGCCGCTCTGGTCTGCGCTGGCAACGGTTATGTACGACTGGCCGAGAACGTGCCGGCCGGCGTAA	MELSSAVQDFVKKNAQDFLGARNIGFNFLNEVASRQCDPGTLLLTSSAVHGIATMASDIDMLCVVDEPVSTEQMATQIHQEGLHLELLLFNAADVHLALGELTSLAQSPALICLQNYSRWDKRNKVPRKYVERLVYGVTNDLTTPYLSALGDLCVVVSRKDLDVFRVNVACSRLAQRSDEPFAAIGYLMNALTAAMNSLLSMSGWVLSNKKWTLRRWNKSRDLVFLDLCPTTWTEVSALWADLAKGPAVLDEALSRIETLLQQMTGRLAPELLRDEPFTGLQGNVARYPLHAKPLWSALATVMYDWPRTCRPA	MNKRLKKSISRYFFIRFLQGLCCMSFFLVFALGISYLWCSERVWYEGEVSYFIVHILHEYWYVLFLGLMIIGCIVIAMINIRCIAQGISDIMQAVRDVNEENEVQIELPDYLADAQAQLTDIKNHVEWNKKTAQEAVQRKNDLIMYLAHDLKTPLTSTIGYLTLLHDEKEISKEVRDKYMGIALKKSLRLEELLNEFFEIARFNFSTMVLEKGNVNMSVMVEQLLYEFKPLFDKKGLTYTIDLEKDVNVYCDVEKMERVFDNLLKNIVNYSYENTEIAITLKANGEQGMLFVIRNHGKTIPKEKCERIFEQFYRLDGSRGTKTGGSGLGLAVVKEIVELHEGTVTCESENEEICFRITI	87.19	gnl|BL_ORD_ID|4822|hsp_num:0	5808			306	513	vancomycin; teicoplanin
BGC0000919.1|Phaseolotoxin_3 # 1647 # 2192 # 1 # ID=1_3;partial=00;start_type=ATG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.566	BGC0000919.1|Phaseolotoxin_3 	1647	2192	+	Loose	1900	24.2534	TriC	33.33	3003681	protein homolog model	n/a	n/a	disinfecting agents and antiseptics	antibiotic efflux	resistance-nodulation-cell division (RND) antibiotic efflux pump	ATGTTTGAAGCACGACAAGACTCAACCTTGCGTTGGTTTCCTCGGCTGACCGGAGGCGTGGGGGTGGAGGGCAATAGCATGGCCCGCGCCATCGTCAGCGCGGCATGGCTGGTGATGTCCGAACTGTATGCCTACCTCGAAGATCTGGAAGGCGCCATGGATGCTCCGGATGCATCGGTGTTGATTAAAGTGAAGATTGCTGAACTGCTGGTGCAAATCGACTGCACGTTGGGGCGCACGGCGGTGCTCGACGAAGAGCACAGATTGCCGTGGTTACTTGAGTACGGCTTGTGCGAGGTGATCAATTTACCCGGGGCTGACATGGCGCGCTTGCTGGGTCTGTTCGCAGCGAATGACGCAACTGAAATCCGTCGAGTAAGCCAGCTGATACGTGATTTGATTGCGGCATTCCCGGGCGAGTTGGTCGATTCGCTGCAAGCGCACAACCAGGGAGGCGTTCTGCGTTTTCTTCGGTCTTCCGACAAGGCGTGTACCGCGTTGGGTTGCGATGCCAGTTTTCTGGTGCCACTGATGAAATCCCTATGA	MFEARQDSTLRWFPRLTGGVGVEGNSMARAIVSAAWLVMSELYAYLEDLEGAMDAPDASVLIKVKIAELLVQIDCTLGRTAVLDEEHRLPWLLEYGLCEVINLPGADMARLLGLFAANDATEIRRVSQLIRDLIAAFPGELVDSLQAHNQGGVLRFLRSSDKACTALGCDASFLVPLMKSL	MKGGFNLSDWALRHQSLVWYLMAVSLVMGVFSYLNLGREEDPSFAIKTMVIQTRWPGATVDDTLEQVTDRIEKKLEELDSLDYVKSYTRPGESTVFVYLKDTTKAGDIPDIWYQVRKKISDIQGEFPQGIQGPGFNDEFGDVFGSVYAFTADGLDFRQLRDYVEKVRLDIRSVKDLGKVQMIGAQNEVIYLNFSTRKLAALGLDQRQVVQSLQAQNAVTPSGVVEAGPERISVRTSGNFRSEKDLQAVNLRVNDRFYRLSDLASISRDFVDPPTSLFRYKGEPAIGLAVAMKEGGNILEFGEALNARMQEITGELPVGVGVHQVSNQAQVVKKAVGGFTRALFEAVVIVLIVSFVSLGLRAGLVVACSIPLVLAMVFVFMEYTDITMQRVSLGALIIALGLLVDDAMITVEMMITRLELGDSLHDSATYAYTSTAFPMLTGTLVTVAGFVPIGLNASSAGEYTFTLFAVIAVALLLSWIVAVLFAPVIAVHILPKTLKHKSEQKKGRIAERFDSLLHLAMRRRWTTIFLTALLFGVSLFLMKFVQHQFFPSSDRPELLVDLNLPQNSSIHETRAVMDRLEATLKDDEDIDHWSAYVGEGAIRFYLPLDQQLQNNFYGQLVIVTKDLEARERVAARLRDRLRKDYVGISTYVQPLEMGPPVGRPIQYRVSGPQIDKVREYAMGLAGVLDGNPNIGDIVYDWNEPGKMLKIDIAQDKARQLGLSSEDVAQIMNSVVTGSAVTQVRDDIYLVNVIGRAEDSERGSLETLESLQIVTPSGTSIPLKAFAKVSYELEQPLVWRRDRKPTITVKASLRGEIQPTDLVARLAPEVKRFADGLPANYRIEVGGTVEESGKAEGPIAKVVPLMLFLMATFLMIQLQSVQKLFLVASVAPLGLIGVVAALLPTGTPMGFVAILGILALIGIIIRNSVILVTQIDAFEKDGKTPWEAVLEATHHRTRPILLTAAAASLGMIPIAREVFWGPMAYAMIGGIVAATLLTLIFLPALYVAWYRIPEPGR	17.83	gnl|BL_ORD_ID|2004|hsp_num:0	2194			276	366	triclosan
BGC0000919.1|Phaseolotoxin_4 # 2189 # 3481 # 1 # ID=1_4;partial=00;start_type=ATG;rbs_motif=None;rbs_spacer=None;gc_cont=0.575	BGC0000919.1|Phaseolotoxin_4 	2189	3481	+	Loose	810	28.1054	cdeA	26.77	3003835	protein homolog model	n/a	n/a	fluoroquinolone antibiotic; disinfecting agents and antiseptics	antibiotic efflux	multidrug and toxic compound extrusion (MATE) transporter	ATGAACACTGAACTGACTGGACGGTCTGTCCCGGTGCCGAAGCAATCCGAGCGTAAAAGCGCCTTCGTTGATCGCTATGGTGCTGTCTTCGGTCGTCAACAGGGCCTGATGTTGAAGATGTCGGGGTTGTCCGCATCCGAAGCGCGTGGCGACGGTGCCTGGGTCGAAGATACTCAGGGTGGACGCTGGCTGGACTTCGGTTCGTTCGGTGTGCACCTACTCGGCCATAGTCATTCAGGCGTGGTATCTGCCCTGGTGGAACAGATCCAGCGTTTTGGGCTTTCCGACGAAAATCTGTCGAACGAACCCATCGTACTGGCGGCCGAGCGGCTATTGGTCATGGCGGGACCTGAGAAGGATAAGGTGATTTTCGGCAATACCGGTTCCGAAGTCGTCGAAGCGGCATTGAAACTTGCCAGGATCGTCACTGGACGGCGGAGGGTCATTGCCTTCGAGCAGGCTTACCACGGGCGCACCGCGGCTGCCTTGAGTGTCAGTCATGGCTACATGCGGCATGCCGGTCTTCTGACTGAAGGTGACGTGGTTTTTTGTCCAATCGACGATCTCGATGCTGTCGCCAACGCGCTGGAGGCAGGCGACATCGCGGCGATCATTATTGAGCCCATACAGGGCGAGGGCGGGATACGCCCTGTGGAGAATGAATTTCTTCGAGGTCTTGGCGACCTGGCCCAGGCTTTTGACTGCCGCTTGATATTTGACGAGATCCAAACGGGCCTGGGGCGTATCGGTAGCCTGCGTGTCGACGTTCCTTGCGACATCCTGCTGTTGGGCAAGGTTCTGGGCGGTGGTGTTTTCCCGATCTCGGCAGCCTTGTTTACGTCGAAGCGTTTTGATGCGGCTGCCCGGGATCCGGTAGTCCACGCTTCGTCTTTTGCCGGTAGTGCCCTGGCCGGTGCCGTCGTCAACGCGGTGCTGGATGTTGTGTCCGCTCCCGATTTCACCCTCAGGGTGCAGCGCTTAGGCGATCGGGTCTTGAGCTATCTCGGCCAGCGCCTTGCAGATAATCCCTTGATTACCGACATCCGTGGCCAGGGCTTGATGATCGGCGTTGAGTTCAAGCGTCTCGATCATGTCGGGGAGATGATCATCGAGGCCGCCAAACGCGACTTGTTGCTCGCTTTCTGTCTCACCGATCCGAAAGTTTTGCGTCTCTACCCGCCAGCCGTCATCAGCGACGCAGATCTCGAAACAGGGCTGGAGCACTTTTGCCAGAGTGTTGAAGCGATCACTCGAACAGAATTCGATAAGGAAATCCCGTTATGCCAGCAGTAA	MNTELTGRSVPVPKQSERKSAFVDRYGAVFGRQQGLMLKMSGLSASEARGDGAWVEDTQGGRWLDFGSFGVHLLGHSHSGVVSALVEQIQRFGLSDENLSNEPIVLAAERLLVMAGPEKDKVIFGNTGSEVVEAALKLARIVTGRRRVIAFEQAYHGRTAAALSVSHGYMRHAGLLTEGDVVFCPIDDLDAVANALEAGDIAAIIIEPIQGEGGIRPVENEFLRGLGDLAQAFDCRLIFDEIQTGLGRIGSLRVDVPCDILLLGKVLGGGVFPISAALFTSKRFDAAARDPVVHASSFAGSALAGAVVNAVLDVVSAPDFTLRVQRLGDRVLSYLGQRLADNPLITDIRGQGLMIGVEFKRLDHVGEMIIEAAKRDLLLAFCLTDPKVLRLYPPAVISDADLETGLEHFCQSVEAITRTEFDKEIPLCQQ	MENLFTRKFTTFEFLKFVSPAIISMIFISLYTIIDGIFVSTLVGSDALASINIVLPIINLVCGFGIMMATGGGAIVSIRMGENRQDEANSTFSFIVLFSLIVGILFTVISYFFIKEISILLGATDKLLPYCITYGKVMILCTPFYILKFIFEYFARTDGNSKFSLFLSVIGGVTNIILDYVFIKYFGMGLLGAAVATAIGIILTCVLGIIYFLSNKSTLKLRKPKTDFRLIRDTMINGSSEMVTELSTGITTFLFNVVALKLAGENGLAALTIVLYAHFLMTSVYLGFAAGVSPLISYNFGAENSDKLKETFKHSLKFIFISSLLVFIIALVFAPFIVRVFVNPDNTVFKLALQGLKIFAFAFLFVGINIFASGFFTAFHNGKISAIISFSRAFVFIIIGIIILPPMLNMTGLWLTVPFAEVITIFISILFIKKYKGRYKY	97.51	gnl|BL_ORD_ID|2083|hsp_num:0	2321			108	471	acriflavine
BGC0000919.1|Phaseolotoxin_5 # 3469 # 3933 # 1 # ID=1_5;partial=00;start_type=ATG;rbs_motif=AGGA;rbs_spacer=5-10bp;gc_cont=0.542	BGC0000919.1|Phaseolotoxin_5 	3469	3933	+	Loose	275	25.409	LEN-14	38.24	3002477	protein homolog model	n/a	n/a	penam; penem	antibiotic inactivation	LEN beta-lactamase	ATGCCAGCAGTAAATACATCACTGAATCTTGGGTCTCTTGAGCTGGAGCGAGTCTGGTCGACCCTTTGTGAGTTTCAGCGTTATCCGGAATTCATGAAGGACGTACTTGACGTCACTATCGAGCAACGTACCGGAAACGAAATCATCAGCACCTGGCGTGTATTGCTAAACGGAAGTGAGTTGACCTGGACCGAGCGCGATCTATTGCTGCCCGACCACCGTATCGTGTTTCAGCAAATCGACGGGGACCTGGAAGTCTGGTCAGGGGAGTGGTCCATCCAGCAGGCGGGGGACGACCTTAGTGTGCAACTGGATGTCTTGTTCGATCTTGGCATTCCGTCCCTGGCCGACGTTCTTCATCCGATCGGGGAGCGAGCGATCCGCGCCAATAGCCGGCAGATGCTGGAGGGTATTCGTGATCGAATCCTGCTATCGCAACTATCGACAGTTGCGGTCGAGGCATAA	MPAVNTSLNLGSLELERVWSTLCEFQRYPEFMKDVLDVTIEQRTGNEIISTWRVLLNGSELTWTERDLLLPDHRIVFQQIDGDLEVWSGEWSIQQAGDDLSVQLDVLFDLGIPSLADVLHPIGERAIRANSRQMLEGIRDRILLSQLSTVAVEA	SLLATLPLAVYAGPQPLEQIKQSESQLSGRVGMVEMDLASGRTLAAWRADERFPMVSTFKVLLCGAVLARVDAGLEQLDRRIHYRQQDLVDYSPVSEKHLTDGMTIGELCAAAITLSDNCAGNLLLATVGGPAGLTAFLRQIGDNVTRLDRW	101.32	gnl|BL_ORD_ID|182|hsp_num:0	200			162	264	
BGC0000919.1|Phaseolotoxin_6 # 3937 # 5073 # 1 # ID=1_6;partial=00;start_type=ATG;rbs_motif=GGAG/GAGG;rbs_spacer=5-10bp;gc_cont=0.577	BGC0000919.1|Phaseolotoxin_6 	3937	5073	+	Loose	550	26.5646	GES-40	54.17	3006169	protein homolog model	n/a	n/a	carbapenem; cephalosporin; penam	antibiotic inactivation	GES beta-lactamase	ATGTCTGCGCAGACCCCTTTGCAATTGATACTGACTGGCGCCAACGGCACCCTCGGCATTCCATTGGTTCGTTCGTTACTCCAGCAGAGCCTGCAGCTTCAACTGCTCTGCCTGTTACGCACTCAAACGTCATGTGATGAATTAGCGGCGACCTTGTCTGCGGTCGAGCGGGCTCGTGTCGAGTTCCTGGTGGTGGACATTTGCGACGCCGGGGCGATGGCTGCTGCCGCCGACAGCCGACCCAAACTCGAATGTGCCCTGGGTATCCACCTGGCAGCCGACGTGTCCTGGGATAAAAGCTGCGAAGACATGACGGCGCTGAATGTCGGCGGGTCGGAAAACTTTTGTCGTTTCCTGCTGCGCCAGGCCGACCGGCCCGCACTGATCTATGTTTCCACTGCTTATACCCAAGTCGAAGACTGGGAGTACCGCAATGGCTACGAAGAGAGCAAGGCCATGGCCGAGCGCTCGCTGCGTGCAAATTTCGGTGAGCGCATCAGCATTTCGACCTTTAGTTGCAGCCTTGTAGTGGGTGACAGCAAGACCGGAGCCATCAGCCGATTCAACGGGCTCTATCCGCTGATCAGGTTCATGGCCGGGTTCAGCCCTCCCTTCTTGGTGGGAAACAAAACCGGTCTGCTCGACATCGTGCCACTTGATTGGGTGGTCGGTGAGTTGCGGGCGATGATCATACGGTTTGCCGCCAGCGGTGTTGCCGAACAGGTGGTGGCGTCTGCCGGAGACAAGCGTATCGGCTACGAACACTTGGTTCGCCTGGTCGAAAATCAACTGGGCGAGGCACGCGAAACGGCCGGCCTGGGAGCCCAGGATCCCGTGCCCATTCTCAAAAGCCGCCAGTGGGATTTCTTGAAGCGTTCGCTATCGGCCTGGAGTCCTGAAGGCATCTCCAAAAATGAGTTTCGTTACTTCGAACGGTTGTTACAAGTCTACGGGGTGTATGCCAGCAGCGACAGGGTTCGGGCGCCGTTGAATGTTTCTCGCCCATCACCGGATCCCGTCGAGTTTCTGCCACAGGTCATCAAGTTCTGGCTTCAACAACATCCACGGGCATTCCGCTCCCGCTCATTGACGTCTTCCGAGGTTCAAGGCGCTGCCACAGGATTGGTCGAGGAGTAA	MSAQTPLQLILTGANGTLGIPLVRSLLQQSLQLQLLCLLRTQTSCDELAATLSAVERARVEFLVVDICDAGAMAAAADSRPKLECALGIHLAADVSWDKSCEDMTALNVGGSENFCRFLLRQADRPALIYVSTAYTQVEDWEYRNGYEESKAMAERSLRANFGERISISTFSCSLVVGDSKTGAISRFNGLYPLIRFMAGFSPPFLVGNKTGLLDIVPLDWVVGELRAMIIRFAASGVAEQVVASAGDKRIGYEHLVRLVENQLGEARETAGLGAQDPVPILKSRQWDFLKRSLSAWSPEGISKNEFRYFERLLQVYGVYASSDRVRAPLNVSRPSPDPVEFLPQVIKFWLQQHPRAFRSRSLTSSEVQGAATGLVEE	MRFIHALLLAAIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGARNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK	131.71	gnl|BL_ORD_ID|3554|hsp_num:0	4623			612	684	
BGC0000919.1|Phaseolotoxin_7 # 5079 # 6062 # 1 # ID=1_7;partial=00;start_type=ATG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.506	BGC0000919.1|Phaseolotoxin_7 	5079	6062	+	Loose	400	28.4906	vanR gene in vanM cluster	31.82	3002928	protein homolog model	n/a	n/a	glycopeptide antibiotic	antibiotic target alteration	glycopeptide resistance gene cluster; vanR	ATGAGTCTGGCAACCGCGGTAGTTTGCGAAAGAAAAGAACGATGTCGACATGAAAAACTGCGTGTCGATCCTCACGTAGTCCACGACTTGATGAAGTTGCGTCCAGGTAAATGTTTCATACAGATAGGCATGCAATGGTTATTGATTGTGTTCGCCGTTTTTTTCGCTAAGTGGGCCAGCAGTTGGCTGGCCTATAGTATTTCCATTGTATGGATCGCTACACGTCAACATGCGTTATTGGTACTGATGCATGATGCTTGCCATTATTTGATCAGTCGTCGGCGCTGGCTCAATGATACGGTGGGTAATCTGTTCCTGGCTTTTCCATTGAGCGTTTGTGTATCCCGTTATCGCCGGCACCATTTGCTCCATCATCGCCATCTCAATACCGAGCTTGATCCCGATATAAAAGATTCACAACTGCCGAAGACACGTATCAGGTTTTATGGGCTGTTGCTGCGCGATGCACTGGGTGTTTCGACACTGATGACACTTAGATCGGTCAACAACTTTGGGCTGTTGGGGTTGTTCGCCAGAGGCAGTCACTGCTCGCGGCTTGATCGGCGTCTGGCAATGGCTTTTATTATTGCCGTGGGCGGGGGGATAACTTGGGTAGGTGGCGGGTGGGACGTGTTATGGCTTTGGGTTGTTCCGGCGTTTACGATACTTCCGTTGATCCTGCGTGTACGCAGTATTGCCGAACACGGGGGAAGGTTAGACCATCCGAATGCCAGTAATGCCCGAAGTATCGATGTGGGTATTATCGAGCGGTTTCTCTGGGCGCCCTGTCATATCAATCGACACTGGGAACATCATCTCTGTCCGGCAGTGCCCACGTATAACTTATCGCTGCTTACTGCACGACTGGCTAGCTTTTTTCCCCAGTCGTCAGCGGCACAACGTACTCAAGGTTACTTTTTTAGTGCTCGGTCGCTGGTGTCGGAGTTGTACCCCAACACCACTCCCCCATGGCTGGCAGATTGA	MSLATAVVCERKERCRHEKLRVDPHVVHDLMKLRPGKCFIQIGMQWLLIVFAVFFAKWASSWLAYSISIVWIATRQHALLVLMHDACHYLISRRRWLNDTVGNLFLAFPLSVCVSRYRRHHLLHHRHLNTELDPDIKDSQLPKTRIRFYGLLLRDALGVSTLMTLRSVNNFGLLGLFARGSHCSRLDRRLAMAFIIAVGGGITWVGGGWDVLWLWVVPAFTILPLILRVRSIAEHGGRLDHPNASNARSIDVGIIERFLWAPCHINRHWEHHLCPAVPTYNLSLLTARLASFFPQSSAAQRTQGYFFSARSLVSELYPNTTPPWLAD	MRRISILIAEDEEEIADLLAIHLEKEGYDVIKVHDGQEALHVIQAQSIDLIILDIMMPKMDGYEVTRQVRAQYNMPIIFLSAKTSDFDKVHGLVIGGDDYITKPFTPIELVARVNAQLRRSMKLNHPQADDKKSILEFGEIVISPDQRTVFLYGENIGLTPKEFDILYLLASHPKKVYSVENIFQQVWNDAYFGGGNTVMVHIRTLRKKLGEDKRKNKLIKTVWGVGYTFNG	140.95	gnl|BL_ORD_ID|4735|hsp_num:0	752			285	405	vancomycin; teicoplanin
BGC0000919.1|Phaseolotoxin_8 # 6110 # 6382 # 1 # ID=1_8;partial=00;start_type=ATG;rbs_motif=AGGAG;rbs_spacer=5-10bp;gc_cont=0.513	BGC0000919.1|Phaseolotoxin_8 	6110	6382	+	Loose	450	26.5646	rmtH	52.63	3003198	protein homolog model	n/a	n/a	aminoglycoside antibiotic	antibiotic target alteration	16S rRNA methyltransferase (G1405)	ATGATGCTGACGGGTAGTGAAATTCAACGAATGCGTGAATTGAAACGCATTGTGATCGAACCATTCGATCCCCGTTTGATAGAGCAGAATTCATATGCCTGCCATTTGGGGAGCGAGATTATCGAGTATGACGCCGAACAGATCGATCCTCATGAGGGCCTGGGGAACTATTCAGCACACTATCCCCGGAAGAAGGGCTGGTCCAGCCTCCCGAAGGCGTTTTTACCTGGGCTCTACCGTCGAATGTATCGGCGGGCTGGATTTTGCGAGTGA	MMLTGSEIQRMRELKRIVIEPFDPRLIEQNSYACHLGSEIIEYDAEQIDPHEGLGNYSAHYPRKKGWSSLPKAFLPGLYRRMYRRAGFCE	MTIEQAAADILSSKKYQLLCPDTVVRILTQEWGRHKKPKQAVERTRERLHGICGAYLAPQVEKQASTALAAGDVQKALALHASTRERLDTYPQLYQFVFENNLPARVLDIACGLNPLMLHRQGVASVWGCDIHQGLGNVLTPYAQKHGWDFTFALHDVLCAPVAASGDMALVFKLLPLLEREQPGAALALLRTLDAPVICVSFPTRSLGGRGKGMHQHYATWFEGLVAPHFTVQHHTLIGDELLYRIQPNPA	35.71	gnl|BL_ORD_ID|33|hsp_num:0	41			390	447	amikacin; tobramycin; arbekacin; gentamicin A; gentamicin
BGC0000919.1|Phaseolotoxin_9 # 6417 # 6632 # 1 # ID=1_9;partial=00;start_type=ATG;rbs_motif=None;rbs_spacer=None;gc_cont=0.505	BGC0000919.1|Phaseolotoxin_9 	6417	6632	+	Loose	500	23.8682	FIM-1	36.36	3004786	protein homolog model	n/a	n/a	carbapenem; cephalosporin	antibiotic inactivation	FIM beta-lactamase	ATGTTCATTCAAACCAGCGCGCCACTGGGGCACACAGGGGCAACGATCTGCTGGACGCTGGAAATTGTGGTCACTCAACCGCTGCGTATCTATGCAGGGACGAAGATTGCCAAAGTGTGTTTCTGGAAAAATTTTGGTGCCGTTCGCGCCTATGAAGGGCGTTATGCAGGCTCGCAAAGTGTCGTTCCTTCAAGAATTATAATGGACCAACCATGA	MFIQTSAPLGHTGATICWTLEIVVTQPLRIYAGTKIAKVCFWKNFGAVRAYEGRYAGSQSVVPSRIIMDQP	MRPLPHSYLKSLVICLLTAFAALTPVVNSGVQAAQPKDVPVTFTAITQGVWMHTSMKHMENWGHVPSNGLIVEKGDFSILVDTAWDDPQTAQIIEWSKDTLKKPIRWAVFTHAHDDKMGGVAALRQQGIVTYAAADSNRMAPQNGLTPAEHDLIFDSEHSTSVLHPLVIFDPGPGHTRDNIVVGLPEQGIVFGGCLIRPSGSTSLGNTADADLAHWKTAVLAVAQRFAEAQQIIPSHGPMAGRELFELTAQLAEKASIPSTP	27.10	gnl|BL_ORD_ID|2173|hsp_num:0	3584			618	711	
